Precigen Delivers Q2 Profitability on PAPZIMEOS Momentum; EU, J-code, and Payer Coverage Support Upside
Aug 4, 2026, 4:04 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The company achieved quarterly profitability led by PAPZIMEOS, underpinning a cash-flow break-even path by year-end 2026. Key earnings-driven catalysts include expanding payer coverage, a 7-year exclusivity moat, and a permanent J-code, all of which reduce regulatory and reimbursement risk and may attract buyers on a improved fundamental print. Similar prior bioscience launches with rapid adoption have yielded outsized, multi-quarter upside when profitability milestones align with reimbursement certainty.
AI summary
What happened, with direct paths to the underlying reporting
Precigen reports Q2 2026 profitability driven by PAPZIMEOS with $53.1M in net revenue, signaling accelerating commercial momentum. The company sees a cash runway to break-even by year-end 2026, aided by broad payer coverage and the seven-year exclusivity. EU EMA progress and pediatric expansion potential add optionality for faster growth.
PAPZIMEOS Q2 2026 net revenue $53.1M; up sharply from prior quarter.
PAPZIMEOS revenue propelled Precigen to quarterly profitability.
Cash & equivalents/investments total $38.7M as of 6/30/2026; cash flow break-even by year-end 2026 expected.
Patient hub enrollment exceeds 500 patients across major centers.
FDA grants seven-year PAPZIMEOS market exclusivity; permanent J-code (J3404) effective 4/1/2026; payer coverage near 100% of insured lives.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Precigen (PGEN) transitioned to a commercial stage with the FDA approval of PAPZIMEOS, generating $3.4 million in revenue in Q4 2025. The therapy's demand is expected to increase…
FDA approves Precigen's Papzimeos for recurrent respiratory papillomatosis (RRP). Papzimeos is the first FDA-approved treatment for adults with RRP. 51% of patients achieved compl…
- Precigen, Inc. (PGEN) reported a quarterly loss of $0.10 per share, missing estimates. - Company's revenue of $1.07 million for March 2024 missed Zacks' estimate by 30.84%. - Pr…
